Everest Medicines (STU:6HN) Interest Expense: €-2.8 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6HN Everest Medicines Ltd STU:6HN
43 GF Score
Price €2.76
GF Value €31.47
! 4 Warning Signs
View Full Analysis

What is Everest Medicines Interest Expense?

Everest Medicines STU:6HN -1.43% 43 Interest Expense is €-2.8 Mil as of Dec. 2025. GuruFocus rates STU:6HN with a GF Score™ of 43/100 and a GF Value™ of €31.47. The stock has 4 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Everest Medicines's interest expense for the six months ended in Dec. 2025 was € -1.4 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was €-2.8 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Everest Medicines's Operating Income for the six months ended in Dec. 2025 was € -7.3 Mil. Everest Medicines's Interest Expense for the six months ended in Dec. 2025 was € -1.4 Mil. Everest Medicines did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Everest Medicines  (STU:6HN) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Everest Medicines's Interest Expense for the six months ended in Dec. 2025 was €-1.4 Mil. Its Operating Income for the six months ended in Dec. 2025 was €-7.3 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was €100.9 Mil.

Everest Medicines's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Everest Medicines did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Everest Medicines Interest Expense Historical Data

* Premium members only.

The historical data trend for Everest Medicines's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Everest Medicines Interest Expense Chart

Everest Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial -0.67 -0.76 -2.96 -2.91 -2.82

Everest Medicines Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.02 -1.38 -1.50 -1.39 -1.43
STU:6HN
43GF Score
Everest Medicines Ltd STU:6HN
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Everest Medicines Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-2.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-2.8 Mil mean?
Everest Medicines (STU:6HN) has a Interest Expense of €-2.8 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Everest Medicines and its competitors.
Is Everest Medicines' Interest Expense too high?
Everest Medicines' current Interest Expense is €-2.8 Mil. Overall, Everest Medicines has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Everest Medicines' Interest Expense compare to VRTX and REGN?
Everest Medicines' Interest Expense of €-2.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Everest Medicines and its competitors. Everest Medicines's current Interest Expense is €-2.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Everest Medicines stock overvalued right now?
Everest Medicines (STU:6HN) has a current Interest Expense of €-2.8 Mil. The stock's GF Value™ is €31.47, compared to a current price of €2.76 — trading 91.2% below its estimated fair value. The current Interest Expense is €-2.8 Mil. Everest Medicines' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Everest Medicines (STU:6HN), the current Interest Expense is €-2.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Everest Medicines (STU:6HN) Overvalued in 2026?

Based on GuruFocus' analysis, Everest Medicines stock appears to be undervalued. The current stock price of €2.76 is trading 91.2% below its estimated GF Value™ of €31.47.

Key valuation signals for STU:6HN:

  • Interest Expense: €-2.8 Mil
  • GF Value™: €31.47 vs. price of €2.76 (91.2% below fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the STU:6HN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Everest Medicines Business Description

Other Exchanges 01952:Hong Kong
Address AIA Financial Center, 866 East Changzhi Road, 17th Floor, Hongkou District, Shanghai, CHN, 200082
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes: Nefecon (TarpeyoTM), EVER001, Eravacycline (Xerava), SPR206, and others. Geographically operates in Mainland China.
43GF Score

Get the complete analysis for STU:6HN

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.76
Price
€31.47
GF Value